- Research article
- Open Access
The effect of soluble E-selectin on tumor progression and metastasis
BMC Cancer volume 16, Article number: 331 (2016)
- The Erratum to this article has been published in BMC Cancer 2016 16:370
Distant metastasis resulting from vascular dissemination of cancer cells is the primary cause of mortality from breast cancer. We have previously reported that E-selectin expression on the endothelial cell surface mediates shear-resistant adhesion and migration of circulating cancer cells via interaction with CD44. As a result of shedding, soluble E-selectin (sE-selectin) from the activated endothelium is present in the serum. In this study, we aimed to understand the role of sE-selectin in tumor progression and metastasis.
We investigated the effect of sE-selectin on shear-resistant adhesion and migration of metastatic breast cancer cells and leukocytes in vitro and in vivo.
We found that sE-selectin promoted migration and shear-resistant adhesion of CD44+ /high breast cancer cell lines (MDA-MB-231 and MDA-MB-468) to non-activated human microvessel endothelial cells (ES-HMVECs), but not of CD44-/low breast cancer cell lines (MCF-7 and T-47D). This endothelial E-selectin independent, sE-selectin-mediated shear-resistant adhesion was also observed in a leukocyte cell line (HL-60) as well as human peripheral blood mononuclear cells (PBMCs). Additionally, the incubation of MDA-MB-231 cells with sE-selectin triggered FAK phosphorylation and shear-resistant adhesion of sE-selectin-treated cells resulted in increased endothelial permeabilization. However, CD44 knockdown in MDA-MB-231 and HL-60 cells resulted in a significant reduction of sE-selectin-mediated shear-resistant adhesion to non-activated HMVECs, suggesting the involvement of CD44/FAK. Moreover, functional blockade of ICAM-1 in non-activated HMVECs resulted in a marked reduction of sE-selectin-mediated shear-resistant adhesion. Finally, the pre-incubation of CD44+ 4 T1 murine breast cancer cells with sE-selectin augmented infiltration into the lung in E-selectin K/O mice and infusion of human PBMCs pre-incubated with sE-selectin stimulated MDA-MB-231 xenografted breast tumor growth in NSG mice.
Our data suggest that circulating sE-selectin stimulates a broad range of circulating cells via CD44 and mediates pleiotropic effects that promote migration and shear-resistant adhesion in an endothelial E-selectin independent fashion, in turn accelerating tissue infiltration of leukocytes and cancer cells.
Tissue infiltration of circulating cells is critical for multiple aspects of tumor progression and metastasis. First, extravasation of circulating leukocytes into the primary tumor aids in the development of a tumor stroma that provides a fertile environment for cancer cells to survive and grow. Second, extravasation of circulating tumor cells into the tissue parenchyma of distant organs gives rise to metastasis. Despite the recognized importance of tissue infiltration in tumor progression and metastasis as well as pathologic alterations in the global serum protein profiles of cancer patients, it is uncertain whether circulating factors in the vascular space extrinsically stimulate circulating cells to infiltrate tissues. During tissue infiltration, inflamed vascular endothelium, characterized by expression of E-selectin and CAMs, functions as a gateway to tissue parenchyma. Tissue infiltration by circulating cells is governed by a multi-step adhesion cascade, mediated by sequential interactions and crosstalk between adhesion molecules expressed on the endothelial cell surface and their counter-receptor ligands expressed on circulating cells [1–4]. A robust interaction is required for this attachment to resist swift blood flow. Weak interaction prevents effective attachment of the circulating cells to the endothelial surface. The initial adhesion of circulating cells subsequently leads to firm attachment that opens the endothelial junction enabling transendothelial migration into tissue parenchyma toward cytokine or chemokine stimuli [5, 6].
Adhesion molecules, such as selectins, ICAM, and VCAM, expressed on the endothelial surface in response to inflammatory stimuli are the primary mediators of tissue infiltration [7, 8]. E-selectin (CD62E, ELAM-1, or LECAM-2) is expressed exclusively on the luminal surfaces of inflamed vasculature  and mediates rolling and vascular adhesion through interaction with carbohydrate ligands [10, 11]. A variety of ligands for E-selectin have been identified in different types of cells; these include CD44 (HCELL) [12–14], Mac-2 binding protein , Muc-1 , death receptor-3 , and ESL-1 . The expression of E-selectin is temporally and spatially limited. E-selectin is shed into circulation (soluble E-selectin: sE-selectin) or internalized rapidly after activation. An abundance of sE-selectin in the serum is indicative of inflammation [19–23], and circulating sE-selectin levels are consistently high among individuals with chronic inflammation compared to their healthy counterparts . Similarly, elevated serum levels of sE-selectin were reported and positively associated with tumor grade, tumor stage, and metastases in breast cancer [3, 25]. Despite the positive associations between sE-selectin and breast cancer progression and metastasis, it is unclear whether sE-selectin plays any functional role in tumor progression. In the present study, we demonstrate that sE-selectin functions as a signaling molecule in circulation with the ability to 1) enhance shear-resistant adhesion and migration of CD44+/high breast cancer cells (BCs) and leukocytes in an endothelial E-selectin independent fashion, 2) activate focal adhesion kinase (FAK), 3) promote homing of CD44+/high BCs to the lung, and 4) stimulate tumor growth and intratumoral infiltration of PBMCs. These findings identify a possible extrinsic mechanism by which an inflammation-associated factor (i.e., sE-selectin) present in circulation pleiotropically stimulates circulating tumor cells toward tumor progression and metastasis.
Cell lines and culture conditions
Human breast cancer cell lines MDA-MB-231, MDA-MB-468, T-47D, and MCF-7, human leukocyte cell line HL-60, and murine breast cancer cell line 4 T1 were purchased from ATCC (Rockville, MD). MDA-MB-231, MDA-MB-468, MCF-7, and 4 T1 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Cellgro) supplemented with 10 % fetal bovine serum (FBS), 2 mM GlutaMAX, and 100U/ml Penicillin-Streptomycin (Life Technology, Grand Island, NY). T-47D and human PBMCs cells were cultured in RPMI-1640 supplemented with 10 % FBS, 2 mM GlutaMAX, and 100U/ml Penicillin-Streptomycin. HL-60 cells were cultured in IMDM supplemented with 20 % FBS, 100U/ml Penicillin-Streptomycin, and Insulin-Transferrin-Selenium (100 mg/L Insulin; 5.5 mg/L Transferrin; 6.7 μg/L Selenium; Corning, Manassas, VA). CD44 knockdown clones were generated by transducing the cells with CD44 shRNA lentivirus or control shRNA (Santa Cruz, CA), followed by selection with puromycin. 4 T1-Luc was generated by transducing 4 T1 cells with luciferase lentivirus (Capital Biosciences) followed by selection using 6 μg/ml puromycin (InvivoGen). Human Microvascular Endothelial cells (HMVECs) and E-selectin-expressing Tet-on inducible HMVECs  were cultured in endothelial basal medium-2 (EBM-2; Lonza) supplemented with 2 % tet-approved FBS and an EGM SingleQuot Kit containing epidermal growth factor (EGF), hydrocortisone, gentamicin, and amphotericin B (GA-1000; Lonza). All cells were cultured in 5 % CO2 humid chambers at 37 °C.
Reagents and antibodies
Recombinant human sE-selectin was purchased from R&D Systems. Monoclonal antibodies for pFAK and total FAK were purchased from Cell Signaling. Blocking antibodies for ICAM and VCAM were purchased from Santa Cruz and Biolegend, respectively. FAK inhibitor II was purchased from Calbiochem.
In vitro cell adhesion assay
HMVECs were grown to confluence in the flow chamber (μ-Slide I 0.4 Luer for cancer cells and 0.2 for leukocytes; Ibidi, Madison, WI) coated with collagen I and fibronectin. The cells (105 cells/ml) were pre-incubated with 100 nM sE-selectin for 10 min and perfused over a 5 min period into the flow chamber in 1 % FBS containing DMEM medium at a shear stress rate of 1 dyn/cm2. Unbound cells were washed off with DMEM containing 1 % FBS. Using a light microscope at a final magnification of 100×, the number of cells that adhered to endothelial cells was determined by counting cells in at least five random fields. The data are expressed as the mean of triplicate experiments.
In vitro permeability assay
HMVECs were grown to confluence on the top-facing side of a collagen-coated 0.4-μm-pore transwell chamber (Corning). MDA-MB-231 cells were pre-incubated with 100 nM sE-selectin for 10 min at 37 °C. MDA-MB-231 cells (2 × 103 cells) suspended in EBM-2 media and 2000-kDa FITC-dextran (final concentration of 1 mg/ml, Sigma-Aldrich) were seeded into the upper chamber, and 600 μl EBM-2 media was added to lower chamber. Then, at the indicated time points, 50-μl aliquots were removed from the lower chamber and the fluorescence was measured at 485/530 nm with a CLARIOstar fluorimeter (BMG Labtech).
Cell migration assay
Transwell migration assays were performed using a 12.0-μm or 5.0-μm pore transwell chamber (Becton Dickinson). Cancer cells (2.5 × 104 cells) or leukocytes (1.0 × 105 cells) suspended in serum-free media were applied to the upper chamber and 100 nM sE-selectin was added to the lower chamber. After overnight incubation at 37 °C, migrated cells were stained using a HEMA 3 staining kit (Pierce) and counted under a light microscope.
Anoikis resistance was measured using ultra-low attachment plates (Corning). Cancer cells (104 cells) were suspended in 1 % FBS containing medium with or without sE-selectin, seeded into 96-well ultra-low attachment plates, and incubated for 72 h. The number of viable and non-viable cells was determined by trypan blue exclusion using a hemocytometer.
All animal housing and handling procedures were in accordance with institutional guidelines at the University of Oklahoma and Thomas Jefferson University. Six-week-old female Balb/C mice (Jackson Laboratory) or E-selectin knockout mice (C.129S4-Sele tm1Dmil/J; Jackson Laboratory) were used for the in vivo cell adhesion assay. Female Balb/C mice or E-selectin knockout mice (n = 3) were injected intravenously with 4 T1-luc murine breast cancer cells (3 × 104 in 100 μl saline) via tail vein. Cancer cells were pre-incubated with 100 nM sE-selectin for 10 min at 37 °C and washed with PBS to remove sE-selectin carry over before injection. Seven days later, whole lungs were harvested and total RNA was isolated using TRIzol (Life Technologies). Total RNA was reverse transcribed using random hexamer primers and SuperScript® III First-Strand Synthesis Supermix (Life Technologies). qPCR reactions (80 cycle) were performed using TaqMan gene expression master mix (Life Technologies) and the Biorad CFX96™ Touch Real-Time PCR Detection System (Biorad). Luciferase and mouse GAPDH primers were used (Life Technologies). Data are presented as delta-Ct relative to an endogenous control, GAPDH. For leukocyte infiltration, MDA-MB-231 breast cancer cells were injected into the mammary fat pads of 7-week-old female NOD SCID IL2 receptor gamma chain knockout mice (NSG mice: NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ; Jackson Laboratory, Bar Harbor, ME). Freshly isolated PBMCs from healthy donors were incubated with 10 μM Calcein AM (BD bioscience, San Jose, CA) for 30 min. After brief a wash, the Calcein positive PBMCs (2 × 107) were incubated with sE-selectin or saline and slowly infused over 1 min via tail vein into NSG mice bearing tumors of approximately 300 mm3(LxWxH). Tumors were harvested to analyze the tissue migration of Calcein-labeled PBMCs. For tumor growth, MDA-MB-231-TGL cell line (a kind gift from Dr. Massague, Memorial Sloan-Kettering Cancer Center) was used. Human PBMCs (1 × 107 cells) that were treated with or without sE-selectin were infused via tail vein once a week. Tumor growth was monitored by measuring bioluminescence using IVIS Lumina XR (Caliper, MA) once a week by intraorbital injection of 100 μl luciferase (15 μg/ml).
Human CD44-APC (IM7) conjugated antibody (BD Biosciences, CA) was used to select shRNA-infected cells using a Coulter MoFlo cell sorter (Beckman Coulter, Brea, CA). For phenotypic analysis of human PBMCs, tissue was homogenized in cold RPMI, filtered through a 50-μm cell strainer, and washed in PBS. The single cell homogenates were incubated with conjugated antibodies (CD4-APCeFluor780, CD45-FITC, CD8-PerCPCy5.5, CD14-PE, and CD11c-APC) for 20 min at 4 °C. Cells were analyzed on an LSRII flow cytometer (BD Bioscience). All data were analyzed with FlowJo software.
All experiments were carried out in triplicate and repeated at least twice independently. The results are presented as Mean ± SD. Comparisons between groups were analyzed using Student’s t-test. Statistical significance is expressed as *p < 0.05; **p < 0.01; ***p < 0.001.
Soluble E-selectin enhances the shear-resistant adhesion, migration, and anoikis-resistant survival of CD44+/high breast cancer cells
To investigate the effect of sE-selectin on factors pertinent to hematogenous metastasis, we evaluated shear-resistant adhesion, migration, and anoikis-resistant survival using two estrogen receptor (ER)-negative/CD44+/high BCs (MDA-MB-231 and MDA-MB-468), two ER-positive/CD44-/low BCs (T-47D and MCF-7), and a line of Tet-on inducible, E-selectin expressing, human microvessel endothelial cells (ES-HMVECs) . A confluent monolayer of ES-HMVECs was grown on a collagen/fibronectin-coated parallel flow chamber and was incubated with or without doxycycline for 4 h to induce the expression of E-selectin. A single cell suspension of BCs was infused into a chamber to recapitulate the shear-resistant adhesion of disseminated/circulating tumor cells to vascular endothelial cells. The adherent BCs were counted. Incubation of MDA-MB-231 and MDA-MB-468 BCs with sE-selectin increased the shear-resistant adhesion to doxycycline-untreated ES-HMVECs (i.e., absence of E-selectin expression on ES-HMVECs) 1.9 fold (p < 0.05) and 2.0 fold (p < 0.001), respectively, compared with adhesion of saline-treated BCs (Fig. 1a). The adhesion of saline-treated MDA-MB-231 and MDA-MB-468 BCs to doxycycline-untreated ES-HMVECs was negligible, but increased significantly when E-selectin expression was induced in ES-HMVECs by doxycycline (1.8 fold and 2.0 fold, respectively, p < 0.001). The extent of shear-resistant adhesion of sE-selectin-treated MDA-MB-231 and MDA-MB-468 BCs to untreated ES-HMVECs was similar to that of saline-treated BCs to activated ES-HMVECs. In contrast, neither sE-selectin nor endothelial E-selectin enhanced the shear-resistant adhesion of ER+/CD44-/low MCF-7 and T47D BCs. These results suggest the involvement of CD44 in sE-selectin-mediated adhesion. Previously, we demonstrated a physical interaction between E-selectin and CD44 isolated from MDA-MB-231 BCs ; we then examined the effect of sE-selectin in shRNA-mediated CD44-knockdown MDA-MB-231 BCs. Soluble E-selectin-induced shear-resistant adhesion was significantly reduced in two CD44 knockdown clones of MDA-MB-231 BCs (clone 28, 0.29 fold, and clone 36, 0.30 fold, p < 0.001) as compared with saline controls (Fig. 1b).
To further examine the role of sE-selectin on migration, we performed a Boyden chamber migration assay. BCs were added to the upper chamber, while the lower chamber contained culture media, with or without sE-selectin. The presence of sE-selectin enhanced migration of CD44+/high MDA-MB-231 BCs (1.8 fold, p = 0.006) and MDA-MB-468 BCs (1.7 fold, p = 005) (Fig. 1c). However, sE-selectin did not affect the migration of CD44-/low MCF-7 BCs or T-47D BCs (Fig. 1c). Soluble E-selectin-induced migration was also significantly reduced in CD44 knockdown clones of MDA-MB-231 BCs (Fig. 1d). Moreover, sE-selectin increased anoikis resistance in MDA-MB-231 BCs (1.36 fold, p < 0.001) and MDA-MB-468 BCs (1.16 fold, p = 0.02), but this effect was not observed in MCF-7 and T-47D BCs (Additional file 1: Figure S1). Therefore, these data suggest that sE-selectin specifically enhances anoikis resistant survival, shear resistant adhesion, and migration of CD44+/high BCs.
Soluble E-selectin enhances shear-resistant adhesion and migration in leukocytes
To further assess the effect of sE-selectin on circulating cells, leukocyte cell line HL-60 and human peripheral blood mononuclear cells (PBMCs) were used in adhesion and migration assays. Leukocytes (105 cells/ml) were infused into a confluent monolayer of parental HMVECs (p-HMVECs) grown on a collagen/fibronectin-coated parallel flow chamber at 1 dyn/cm2 for 5 min and the adherent cells were counted. Consistent with the data from analysis of BCs, sE-selectin enhanced the shear-resistant adhesion of HL-60 (1.6 fold, p < 0.001) and PBMCs (2.1 fold, p < 0.001) to non-activated pHMVEC (Fig. 2a). Additionally, sE-selectin enhanced the migration of HL-60 (2.4 fold, p < 0.001), and PBMCs (3.6 fold, p < 0.001) (Fig. 2b). Functional blockade of CD44 in HL-60 using CD44 blocking antibody or a knockdown resulted in reductions of sE-selectin-mediated adhesion to non-activated p-HMVECs (p < 0.001). Taken together, these results indicate that sE-selectin may have biological function via CD44 in a broad range of circulating cells including leukocytes and cancer cells.
The shear-resistant adhesion of sE-selectin-treated MDA-MB-231 BCs increases the permeability of non-activated p-HMVECs
While leaky endothelium is a hallmark of tumor-associated vasculatures, under physiologic conditions, endothelial cells are connected through tight junctions. Adhesion of cancer cells to the activated endothelium is reported to induce endothelial permeability for subsequent transendothelial migration [27, 28]. We next evaluated whether the shear-resistant adhesion of sE-selectin-treated MDA-MB-231 BCs enhanced the permeability of non-activated p-HMVECs. A single cell suspension of MDA-MB-231 BCs was pre-incubated with sE-selectin or saline. After a brief spin followed by washing with PBS, the cells were layered onto a confluent monolayer of non-activated p-HMVECs with 2000 kDa FITC-dextran as a fluorescent tracer. Following the addition of sE-selectin-treated MDA-MB-231 cells, a steep increase in fluorescent leakage through the HMVEC monolayer was observed (Fig. 3a). In contrast, the adhesion of saline-treated MDA-MB-231 BCs to non-activated p-HMVECs did not have a significant effect on endothelial permeabilization over the course of the 60 min assay (Fig. 3a). Incubation of p-HMVECs with sE-selectin alone had no effect on endothelial permeability (data not shown). To confirm increased endothelial permeability, the endothelial junction was immunostained after the adhesion of BCs to non-activated p-HMVECs. A single cell suspension of MDA-MB-231 BCs was treated with sE-selectin and then washed with PBS to remove sE-selectin. The cells were infused into a flow chamber at a rate of 1 dyn/cm2 for 5 min. After a brief wash, the cells were fixed for immunostaining with VE-cadherin. The shear-resistant adhesion of sE-selectin-treated MDA-MB-231 BCs to non-activated p-HMVECs resulted in the appearance of a visible gap and disappearance of VE-cadherin surface expression (Fig. 3b). These data suggest that the adhesion of sE-selectin treated CD44+/high BCs permeabilizes non-activated endothelium.
Soluble E-selectin activates focal adhesion kinase
To determine the underlying mechanism of sE-selectin-mediated adhesion and migration, a single cell suspension of MDA-MB-231 BCs was incubated with sE-selectin for 5 to 60 min. Soluble E-selectin triggered the phosphorylation of focal adhesion kinase (FAK) at Tyr-397 after 5 min of incubation; whereas there were no changes in total FAK expression (Fig. 4a). However, sE-selectin did not affect FAK phosphorylation in the CD44sh 28 clone (Fig. 4a), suggesting the involvement of CD44 in sE-selectin-mediated FAK phosphorylation. To confirm the involvement of FAK signaling in sE-selectin-mediated effects, adhesion assays were performed using pathway-specific inhibitors at a concentration that did not affect cell viability (Additional file 1: Figure S2). Suspensions of MDA-MB-231 or HL-60 cells were co-incubated with sE-selectin and FAK inhibitor (FAK inhibitor II, 5 μM) for 30 min. After a brief spin followed by washing with PBS, the cells were then infused into parallel flow chambers. FAK inhibitor II abolished sE-selectin-mediated shear-resistant adhesion to non-activated HMVECs (Fig. 4b).
Pre-activation of 4 T1 BCs with sE-selectin results in enhanced homing in vivo
To validate the effect of sE-selectin on hematogenous metastasis, we used a mouse model of forced lung metastasis. Murine 4 T1 BCs expressing luciferase (4T1-Luc) were pre-incubated with mouse sE-selectin and injected into wild-type Balb/C or E-selectin knockout mice via tail vein. Seven days after the injection, the mice were perfused with warm saline to remove residual cells in the circulation. Relative luciferase mRNA expression was measured in the lung. Pre-incubation of 4 T1 cells with sE-selectin increased homing to the lung by 2.5 fold (p = 0.03) in wild-type mice and 1.7 fold (p = 0.04) in E-selectin knockout mice compared with saline-treated 4 T1-Luc (Fig. 5a). The increased extent of lung homing in wild-type mice may be a consequence of endogenous E-selectin expression on the vessel or sE-selectin shed after activation in wild-type mice. To identify cellular adhesion molecules (CAMs) that support endothelial E-selectin-independent/sE-selectin-mediated shear-resistant adhesion, functional blocking antibodies against ICAM or VCAM were used to pretreat non-activated p-HMVECs for 1 h prior to the flow adhesion assay. The pre-incubation of non-activated p-HMVECs with ICAM-1 blocking antibody resulted in a significant reduction of sE-selectin-mediated shear-resistant adhesion; whereas, VCAM-1 blockade did not affect sE-selectin-mediated shear-resistant adhesion (Fig. 5b).
Pre-activation of human PBMCs with sE-selectin stimulates tumor growth
To confirm pleiotropic effects of sE-selectin, we next explored the biological consequences of leukocyte activation by sE-selectin on tumor growth in vivo. Human PBMCs were freshly isolated from healthy donors and labeled with Calcein AM, then pre-treated with sE-selectin for 30 min at 37 °C. The PBMCs were infused via tail vein into NSG mice bearing human breast tumors derived from MDA-MB-231. Infiltration of Calcein positive PBMCs was measured by fluorescence-activated cell sorting (FACS) and visualized by fluorescent microscopy. Following a single intravenous infusion of sE-selectin-treated PBMCs, 1.45 ± 0.08 % of tumor cells were Calcein-positive, whereas, only 0.14 ± 0.1 % of tumor cells were Calcein-positive in mice receiving saline-treated PBMCs. This amounts to a ten-fold increase in PBMC infiltration when PBMCs are exposed to sE-selectin prior to infusion (p < 0.001) (Fig. 6a). Fluorescence microscopic analysis further confirmed that pre-incubation of PBMCs with sE-selectin resulted in an increased infiltration of Calcein-positive PBMCs into tumors, compared with tumor from mice infused with saline-treated PBMCs (Fig. 6a). Next, we evaluated whether the infiltration of sE-selectin-treated PBMCs into the tumor affected tumor growth. PBMCs treated with or without sE-selectin were infused at day 18 and 25 into NSG mice bearing MDA-MB-231 breast tumors carrying the luciferase gene (n = 5). Tumor growth was measured weekly at day 10, 16, 22 and 29 by bioluminescence. PBMCs were infused, and on day 22 (4 days post- PBMC infusion), we found that infusion of sE-selectin-treated PBMCs had increased tumor growth by 3.6 fold when compared to day 16 (prior to infusion). In contrast, in the mice receiving saline-treated PBMCs, only 1.4 fold tumor growth was noted. The differences in tumor growth rates between these groups were significant at four days after infusion (2.6 fold, p < 0.05). This trend remained the same at 29 days (Fig. 6b). FACS analysis of tumors further confirmed the presence of human CD45+ cells after two consecutive infusions of human PBMCs (Fig. 6c). Infusion of sE-selectin treated of PBMCs increased intratumoral infiltration by human CD4+ T-lymphocytes (20.2 %) significantly more than infusion of saline treated control PBMCs (11.5 %), but did not affect infiltration of CD8+ T-lymphocytes or CD68+ cells. Of note, the CD4/CD8 ratios of PBMCs used in this study were almost the same (CD4: 39.1, CD8: 37.2; Additional file 1: Figure S3). These data suggest that sE-selectin is a biologically functional signaling molecule in circulation after shedding and enhances the shear-resistant adhesion and migration of a broad range of CD44+ circulating cells (metastatic cancer cells or leukocytes), which additively promote disease progression via stromal development and homing of metastatic BCs to the lung.
Circulating E-selectin, sE-selectin, is a byproduct of endothelial E-selectin that originates from the external domain of E-selectin expressed on activated endothelium as a result of enzymatic cleavage or shedding from damaged or activated endothelial cells . Several studies have reported chemotactic effects of sE-selectin in different cell types, including endothelial cells and leukocytes [30–32]. However, the effects of sE-selectin in tumor progression and metastasis is largely unknown. We and others have previously reported that the engagement of CD44 with endothelial E-selectin mediates shear-resistant adhesion of BCs and leukocytes to endothelial cells [13, 14, 33]. In addition to describing the roles of endothelial E-selectin, we found that sE-selectin functions as a circulating signaling molecule that potentiates shear-resistant adhesion and migration of CD44+/high BCs and leukocytes in an endothelial E-selectin independent fashion and facilitates tumor progression and metastasis.
The adhesion cascade is governed by cell-cell interactions between circulating cells and endothelial cells via a sequential affinity interaction between adhesion molecules and the counter-receptor ligand. Thus, the ablation of adhesion molecules, such as selectins, ICAM-1, or VCAM-1, significantly impairs leukocyte infiltration. Given the E-selectin’s integral role in tissue infiltration as the first step mediator of adhesion, endothelial E-selectin-independent homing and shear-resistant adhesion of BCs and leukocytes were unexpected. Our data demonstrate that sE-selectin-mediated activation of the CD44/FAK axis of BCs enables ICAM-1-dependent adhesion at low shear stress, bypassing the requirement for engagement with endothelial E-selectin. A bypass of initial adhesion via endothelial E-selectin may occur when abundant CD44+ cells and circulating sE-selectin encountered endothelium expressing ICAM-1 at low shear stress. Similar bypass mechanism was reported by Thankamony and Sackstein as a novel paradigm of cell migration termed the “step 2-bypass pathway’”. The step 2-bypass pathway permits transendothelial migration of mesenchymal stem cells through interaction of endothelial VCAM-1 with activated VLA-4 without engagement of the chemokine receptors (CXCR4 and SDF-1) . These data suggest the presence of alternative adhesion mechanisms that are supported by CAMs. In fact, the expression of CAMs is primarily induced by inflammatory cytokines; however, low levels of constitutive expression occurs in some organs and endothelial cell lines [35–37]. Additionally, double knockout of ICAM/VCAM is lethal [38, 39], while triple knockout of selectins (E-, P-, and L-selectin) does not completely ablate tissue infiltration of leukocytes to wounded areas . These collectively indicate the presence of a selectin-independent alternative adhesion, which may be compensated by constitutive CAMs expression. This poses the question of whether individuals with breast cancer and synchronous chronic inflammation who have elevated sE-selectin and CD44+ circulating tumor cells (CTCs) are predisposed to increased risk of organ metastasis. Our data suggested that serum sE-selectin levels were associated with tumor size (Additional file 1: Figure S4). Additionally, several studies demonstrated positive correlations between high sE-selectin levels and worse clinical outcome [25, 41–43]. Sheen-Chen et al., reported that an elevated level of sE-selectin is significantly associated with advanced tumor size, lymph node involvement, metastasis, high histology grade, and reduced overall survival in breast cancer. The study further indicated that women with ER-negative breast tumors had a significantly higher level of sE-selectin than those with ER-positive breast tumors . Similarly to cancer, elevated sE-selectin was also noted in individuals with chronic inflammation disorders including arthritis , diabetes , atherosclerosis , and alcoholism . Our data demonstrated cellular responses to sE-selectin were concentration dependent and reached a plateau at 100 nM (Additional file 1: Figure S5); therefore, we used 100 nM sE-selectin in this study (equal to approx. 5.8 μg/ml when calculated as MW: 60 kDa). While the association of tissue inflammation and cancer progression has been reported [48, 49], future study should address a possible link regarding how chronic inflammation affects cancer cell behavior in vascular space.
The effect of sE-selectin was highly specific to CD44+/high BCs; its effect was minor or undetectable in CD44-/low BCs and CD44 K/D MDA-MB-231 BCs. CD44 (HCELL) , belongs to a family of cell-surface glycoproteins, and differential forms of CD44 (e.g., CD44s and CD44v) are expressed in a variety of human leukocytes and solid tumors. Despite its lack of intrinsic catalytic activity, CD44 plays a role in the activation of signaling pathways through association with intracellular and extracellular proteins. CD44 interacts with various soluble extracellular components or ECM. Ligand binding to CD44 has been associated with numerous cellular processes such as migration, adhesion, signaling, and proliferation . For example, the interaction of CD44 and its ligand, hyaluronic acid (HA), results in proliferation of eosinophils , B-cells , T-cells , keratinocytes , and human melanoma cells . In addition to HA, L-selectin and E-selectin are reported to be ligands for distinct glycoforms of CD44 or CD44v, respectively . The interaction of CD44 with Src family protein kinase, Rho-kinase, Tiam 1, and Vav2 triggers intracellular activation of PI3K, Ras, and Rac1, which promote cell migration, proliferation, and survival [57–61]. Although mounting evidence suggests the involvement CD44 in tumor progression, the roles of CD44 as well as its utility as a biomarker for primary tumors remains controversial due to its dual functions as a tumor promoter or suppressor and altered expression in CD44v [37, 38]. However, recent studies highlighted the positive association of CD44+ CTCs with hematogenous metastasis. The presence of CD44+ CTCs is linked to bone metastasis  and correlates with poor prognosis in breast cancer [63, 64]. While the CD44 has been used as a stem cell marker, our data suggest that CD44 may have functional role in hematogenous metastasis in the circulation 1) as a ligand for endothelial E-selectin at the pre-metastatic niche  and 2) as a signaling molecule that mediates sE-selectin-induced extrinsic stimuli in circulating cells.
Abundant leukocyte infiltration into the tumor is associated with poor prognosis in many types of cancer including breast, prostate, lung cancer, and melanoma [48, 65, 66]. Our results demonstrate that sE-selectin enhancement of leukocyte migration is partially mediated by CD44. We used humanized NOD SCID IL2R-γ chain knockout mice, which are deficient in T-lymphocytes, B-lymphocytes, and NK cells, to recapitulate the effect of crosstalk between the human immune system and human cancer cells. Mice receiving human PBMCs treated with human sE-selectin showed rapid tumor growth, which coincided with increased intratumoral infiltration of PBMCs, in particular, CD4+ T-lymphocytes (Fig. 6c). Although we expected the CD4+/CD8+ balance shift to trigger pro-inflammatory signaling that would lead to an increase in the human CD68+ macrophage population, no change was noted in CD68+ cells or CD8+ T-lymphocytes. A separate study showed that sE-selectin-mediated tumor growth was not as significant when mouse splenocytes were infused into athymic nu/nu mice bearing xenograft tumors derived from MDA-MB-231 cells (data not shown), although infiltration of mouse PBMCs into the tumor was more extensive than that of human PBMCs (Additional file 1: Figure S6). Possibly, there is a slight discordance between adaptive immune cells from human and innate immune cells and vessels of mice.
In conclusion, we proposed possible simultaneous and multifaceted effects of E-selectin in tumor growth and metastasis in Fig. 7: endothelial E-selectin mediates the shear-resistant adhesion of circulating tumor cells and immune cells to inflamed vessels (a), but not to non-inflamed vessels (b); sE-selectin shed into circulation accelerates homing of CD44+ BCs into tissue via non-inflamed vessels, endothelial E-selectin independent/ICAM dependent manner (c); sE-selectin accelerates the infiltration of CD4+ lymphocytes into the tumor to contribute to the development of inflammatory stromal (d).
Soluble E-selectin (sE-selectin) is shed into the circulation from the activated endothelium. We investigated the effect of sE-selectin on shear-resistant adhesion and migration of metastatic breast cancer cells and leukocytes. Our data suggest that sE-selectin promotes migration and shear-resistant adhesion of circulating cells to non-activated HMVECs via CD44/FAK. This sE-selectin-mediated pleiotropic effects result in enhancement of homing of CD44+/high BCs and immune cells to the lung and tumor, respectively. These findings identify a possible extrinsic mechanism by which serum factor stimulates circulating tumor cells toward tumor progression and metastasis.
breast cancer cells
cell adhesion molecules
allophycocyanin-conjugated CD11c antibody
phycoerythrin-conjuated CD14 antibody
- CD44 K/D:
CD44 knock down
homing cell adhesion molecule (HCAM), phagocytic glycoprotein-1(Pgp-1)
CD44 standard from
shRNA targeting CD44
CD44 variant isoforms
fluorescein isothiocyanate-conjugated CD44 antibody
allophycocyanin-eFluor780-conjugated CD4 antibody
cluster of differentiation 68 positive
peridinin chlorophyll-cyanine5.5-conjugated antibody
Chemokine receptor 4
Dulbecco’s modified eagle medium
dyne per one square centimeter
estrogen receptor positive
endothelial leukocyte adhesion molecule, CD62E
E-selectin ligand 1
Focal adhesion kinase
hematopoietic cell E-selectin/L-selectin Ligand
human microvessel endothelial cells
Intercellular adhesion molecules
- NSG mice:
NOD scid gamma mice
peripheral blood mononuclear cells
phosphorylated focal adhesion kinase
ras-related C3 botulinum toxin substrate 1
rat sarcoma viral oncogene
stromal cell-derived factor 1
proto-oncogene tyrosine kinase
vascular cell adhesion molecules
vascular endothelial cadherin
very late antigen-4 (Integrin alpha4 beta1)
Berg EL, Robinson MK, Mansson O, Butcher EC, Magnani JL. A carbohydrate domain common to both sialyl Le(a) and sialyl Le(X) is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1. J Biol Chem. 1991;266(23):14869–72.
Welply JK, Keene JL, Schmuke JJ, Howard SC. Selectins as potential targets of therapeutic intervention in inflammatory diseases. Biochim Biophys Acta. 1994;1197(2):215–26.
Zetter BR. Adhesion molecules in tumor metastasis. Semin Cancer Biol. 1993;4(4):219–29.
Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9(4):274–84.
Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol. 2005;6(12):1182–90.
Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7(9):678–89.
Laubli H, Borsig L. Selectins promote tumor metastasis. Semin Cancer Biol. 2010;20(3):169–77.
Woodward J. Crossing the endothelium: E-selectin regulates tumor cell migration under flow conditions. Cell Adh Migr. 2008;2(3):151–2.
Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol. 1993;11:767–804.
Cotran RS, Gimbrone Jr MA, Bevilacqua MP, Mendrick DL, Pober JS. Induction and detection of a human endothelial activation antigen in vivo. J Exp Med. 1986;164(2):661–6.
Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone Jr MA. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci U S A. 1987;84(24):9238–42.
Dimitroff CJ, Lee JY, Rafii S, Fuhlbrigge RC, Sackstein R. CD44 is a major E-selectin ligand on human hematopoietic progenitor cells. J Cell Biol. 2001;153(6):1277–86.
Kang SA, Hasan N, Mann AP, Zheng W, Zhao L, Morris L, Zhu W, Zhao D, Suh KS, Dooley WC, et al. Blocking the Adhesion Cascade at the Pre-metastatic Niche for Prevention of Breast Cancer Metastasis. Mol Ther. 2015;23(6):1044–54.
Zen K, Liu DQ, Guo YL, Wang C, Shan J, Fang M, Zhang CY, Liu Y. CD44v4 is a major E-selectin ligand that mediates breast cancer cell transendothelial migration. PLoS One. 2008;3(3):e1826.
Shirure VS, Reynolds NM, Burdick MM. Mac-2 binding protein is a novel E-selectin ligand expressed by breast cancer cells. PLoS One. 2012;7(9):e44529.
Geng Y, Yeh K, Takatani T, King MR. Three to Tango: MUC1 as a Ligand for Both E-Selectin and ICAM-1 in the Breast Cancer Metastatic Cascade. Front Oncolo. 2012;2:76.
Gout S, Morin C, Houle F, Huot J. Death receptor-3, a new E-Selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation. Cancer Res. 2006;66(18):9117–24.
Dimitroff CJ, Descheny L, Trujillo N, Kim R, Nguyen V, Huang W, Pienta KJ, Kutok JL, Rubin MA. Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells. Cancer Res. 2005;65(13):5750–60.
Gearing AJ, Hemingway I, Pigott R, Hughes J, Rees AJ, Cashman SJ. Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1: pathological significance. Ann N Y Acad Sci. 1992;667:324–31.
Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today. 1993;14(10):506–12.
Fassbender K, Mossner R, Motsch L, Kischka U, Grau A, Hennerici M. Circulating selectin- and immunoglobulin-type adhesion molecules in acute ischemic stroke. Stroke. 1995;26(8):1361–4.
Cowley HC, Heney D, Gearing AJ, Hemingway I, Webster NR. Increased circulating adhesion molecule concentrations in patients with the systemic inflammatory response syndrome: a prospective cohort study. Crit Care Med. 1994;22(4):651–7.
Koch AE, Turkiewicz W, Harlow LA, Pope RM. Soluble E-selectin in arthritis. Clin Immunol Immunopathol. 1993;69(1):29–35.
Leeuwenberg JF, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, Jeunhomme TM, Ahern TJ, Buurman WA. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology. 1992;77(4):543–9.
Hebbar M, Revillion F, Louchez MM, Vilain MO, Fournier C, Bonneterre J, Peyrat JP. The relationship between concentrations of circulating soluble E-selectin and clinical, pathological, and biological features in patients with breast cancer. Clin Cancer Res. 1998;4(2):373–80.
Mann AP, Somasunderam A, Nieves-Alicea R, Li X, Hu A, Sood AK, Ferrari M, Gorenstein DG, Tanaka T. Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting. PloS one 2010;5(9):e13050.
Mierke CT. Endothelial cell’s biomechanical properties are regulated by invasive cancer cells. Mol Biosyst. 2012;8(6):1639–49.
Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014;14(9):598–610.
Pigott R, Dillon LP, Hemingway IH, Gearing AJ. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun. 1992;187(2):584–9.
Lo SK, Lee S, Ramos RA, Lobb R, Rosa M, Chi-Rosso G, Wright SD. Endothelial-leukocyte adhesion molecule 1 stimulates the adhesive activity of leukocyte integrin CR3 (CD11b/CD18, Mac-1, alpha m beta 2) on human neutrophils. J Exp Med. 1991;173(6):1493–500.
Kumar P, Hosaka S, Koch AE. Soluble E-selectin induces monocyte chemotaxis through Src family tyrosine kinases. J Biol Chem. 2001;276(24):21039–45.
Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature. 1995;376(6540):517–9.
Katayama Y, Hidalgo A, Chang J, Peired A, Frenette PS. CD44 is a physiological E-selectin ligand on neutrophils. J Exp Med. 2005;201(8):1183–9.
Thankamony SP, Sackstein R. Enforced hematopoietic cell E- and L-selectin ligand (HCELL) expression primes transendothelial migration of human mesenchymal stem cells. Proc Natl Acad Sci U S A. 2011;108(6):2258–63.
Henninger DD, Panes J, Eppihimer M, Russell J, Gerritsen M, Anderson DC, Granger DN. Cytokine-induced VCAM-1 and ICAM-1 expression in different organs of the mouse. J Immunol. 1997;158(4):1825–32.
Fox SB, Turner GD, Gatter KC, Harris AL. The increased expression of adhesion molecules ICAM-3, E- and P-selectins on breast cancer endothelium. J Pathol. 1995;177(4):369–76.
Schweitzer KM, Drager AM, van der Valk P, Thijsen SF, Zevenbergen A, Theijsmeijer AP, van der Schoot CE, Langenhuijsen MM. Constitutive expression of E-selectin and vascular cell adhesion molecule-1 on endothelial cells of hematopoietic tissues. Am J Pathol. 1996;148(1):165–75.
Gurtner GC, Davis V, Li H, McCoy MJ, Sharpe A, Cybulsky MI. Targeted disruption of the murine VCAM1 gene: essential role of VCAM-1 in chorioallantoic fusion and placentation. Genes Dev. 1995;9(1):1–14.
Kwee L, Baldwin HS, Shen HM, Stewart CL, Buck C, Buck CA, Labow MA. Defective development of the embryonic and extraembryonic circulatory systems in vascular cell adhesion molecule (VCAM-1) deficient mice. Development. 1995;121(2):489–503.
Robinson SD, Frenette PS, Rayburn H, Cummiskey M, Ullman-Cullere M, Wagner DD, Hynes RO. Multiple, targeted deficiencies in selectins reveal a predominant role for P-selectin in leukocyte recruitment. Proc Natl Acad Sci U S A. 1999;96(20):11452–7.
Sheen-Chen SM, Eng HL, Huang CC, Chen WJ. Serum levels of soluble E-selectin in women with breast cancer. Br J Surg. 2004;91(12):1578–81.
Eichbaum MH, de Rossi TM, Kaul S, Bastert G. Serum levels of soluble E-selectin are associated with the clinical course of metastatic disease in patients with liver metastases from breast cancer. Oncol Res. 2004;14(11-12):603–10.
O’Hanlon DM, Fitzsimons H, Lynch J, Tormey S, Malone C, Given HF. Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur J Cancer. 2002;38(17):2252–7.
Klimiuk PA, Fiedorczyk M, Sierakowski S, Chwiecko J. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis. Scand J Rheumatol. 2007;36(5):345–50.
Cakar M, Balta S, Sarlak H, Akhan M, Demirkol S, Karaman M, Ay SA, Kurt O, Cayci T, Inal S, et al. Arterial stiffness and endothelial inflammation in prediabetes and newly diagnosed diabetes patients. Arch Endocrinol Metab. 2015;59(5):407–13.
Kvasnicka T, Kvasnicka J, Ceska R, Grauova B, Vrablik M. Increasing plasma levels of soluble cell adhesion molecules (sE-Selectin, sP-Selectin and sICAM-1) in overweight adults with combined hyperlipidemia. Sb Lek. 2001;102(4):473–7.
Sacanella E, Estruch R, Badia E, Fernandez-Sola J, Nicolas JM, Urbano-Marquez A. Chronic alcohol consumption increases serum levels of circulating endothelial cell/leucocyte adhesion molecules E-selectin and ICAM-1. Alcohol Alcohol. 1999;34(5):678–84.
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.
Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell. 2006;124(4):823–35.
Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241–319.
Hamann KJ, Dowling TL, Neeley SP, Grant JA, Leff AR. Hyaluronic acid enhances cell proliferation during eosinopoiesis through the CD44 surface antigen. J Immunol. 1995;154(8):4073–80.
Rafi A, Nagarkatti M, Nagarkatti PS. Hyaluronate-CD44 interactions can induce murine B-cell activation. Blood. 1997;89(8):2901–8.
Galandrini R, Galluzzo E, Albi N, Grossi CE, Velardi A. Hyaluronate is costimulatory for human T cell effector functions and binds to CD44 on activated T cells. J Immunol. 1994;153(1):21–31.
Kaya G, Rodriguez I, Jorcano JL, Vassalli P, Stamenkovic I. Selective suppression of CD44 in keratinocytes of mice bearing an antisense CD44 transgene driven by a tissue-specific promoter disrupts hyaluronate metabolism in the skin and impairs keratinocyte proliferation. Genes Dev. 1997;11(8):996–1007.
Ahrens T, Assmann V, Fieber C, Termeer C, Herrlich P, Hofmann M, Simon JC. CD44 is the principal mediator of hyaluronic-acid-induced melanoma cell proliferation. J Invest Dermatol. 2001;116(1):93–101.
Dimitroff CJ, Lee JY, Fuhlbrigge RC, Sackstein R. A distinct glycoform of CD44 is an L-selectin ligand on human hematopoietic cells. Proc Natl Acad Sci U S A. 2000;97(25):13841–6.
Ilangumaran S, Briol A, Hoessli DC. CD44 selectively associates with active Src family protein tyrosine kinases Lck and Fyn in glycosphingolipid-rich plasma membrane domains of human peripheral blood lymphocytes. Blood. 1998;91(10):3901–8.
Bourguignon LY, Zhu H, Shao L, Chen YW. CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. J Biol Chem. 2000;275(3):1829–38.
Bourguignon LY, Zhu H, Shao L, Chen YW. CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration. J Biol Chem. 2001;276(10):7327–36.
Bourguignon LY, Zhu H, Zhou B, Diedrich F, Singleton PA, Hung MC. Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth. J Biol Chem. 2001;276(52):48679–92.
Bourguignon LY, Singleton PA, Zhu H, Diedrich F. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J Biol Chem. 2003;278(32):29420–34.
Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bauerle T, Wallwiener M, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013;31(6):539–44.
Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009;11(4):R46.
Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D, Georgoulias V. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 2010;288(1):99–106.
Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep. 2005;14(2):425–31.
Leek RD, Landers RJ, Harris AL, Lewis CE. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer. 1999;79(5-6):991–5.
We thank Mrs. Lynsie Morris for technical assistance.
This work was supported by the Department of Defense (W81XWH-11-1-0238 to T.T), the National Institutes of Health (1R01CA160271-01A1 to T.T), the American Cancer Society (IRG-08-060-04), and the Pennsylvania Breast Cancer Coalition (T.T).
SK and CB have made substantial contributions to design and/or acquisition of data, or data analysis and interpretation of data. SB, NH, VG, BT, MK, and YM have been involved in data acquisition, revising it critically for important content. TT, HR, WR, DG, and KSS have been involved in drafting the concept, manuscript, and given final approval of the version to be published. All authors have read and approved the contents of final version of the manuscript.
The authors declare that they have no competing interests.
Consent for publication
All authors have read and approved the contents of final version of the manuscript and consented for publication.
Ethics approval and consent to patients
Animal studies received specific ethical institutional committee approval from Institutional Animal Care and Use Committee of the Thomas Jefferson University and University of Oklahoma. All cell lines used in this study were obtained from commercial sources or investigator under MTA agreement; no clinical specimens or human subjects were employed.
Supplementary Figure 1. Soluble E-selectin enhances the anoikis resistance of ER-negative BCs: BCs were suspended (104 cells) in 1% FBS media with or without sE-selectin, and seeded in ultra-low attachment plates. The data represent the increased percentage of surviving cells with sE-selectin. The data shown are Mean ± SD. Supplementary Figure 2. The effect of FAK kinase inhibitors on cell viability: (a) HL-60 cells were incubated with the indicated concentrations of FAK inhibitor for 30 min. The viable cells were counted using a Neubauer hemocytometer 24 hours later. (b) MDA-MB-231 cells were incubated with the indicated concentrations of FAK inhibitor for 30 min. The cell viability was measured by MTT assay. Supplementary Figure 3. Profile of human PBMCs: PBMCs were isolated from freshly isolated human buffy coat of healthy donors. PBMCs were analyzed by flow cytometry using a FACS Calibur. Supplementary Figure 4. Detection of sE-selectin in the serum from mice bearing tumor: MDA-MB-231 cells (3x104 or 3x105 cells) were injected into mice (n=4). Two weeks later, whole blood was collected and serum was collected. Soluble E-selectin level was measured by ELISA. The data shown are Mean ± SD. Supplementary Figure 5. Soluble E-selectin enhances migration of MDA-MB-231 in sE-selectin dose dependent manner: Boyden chamber assay was performed. The migrated cells were stained using an HEMA3 staining kit and were counted under light microscopy. Data were expressed as percentage of control (saline treated as 100%). The data represent Mean ± S.D. Supplementary Figure 6. Mouse splenocyte infiltration into human tumor: Mouse splenocytes were isolated from Athymic nu/nu mice and labeled with Calcein AM (green). The labeled splenocytes (107 cells) were infused intravenously into mice bearing tumors derived from MDA-MB-231 BCs. Tumors were harvested and frozen sections were counterstained with Hoechst 33342 (blue) and visualized using a fluorescent microscope at ×200. (PPTX 4183 kb)
About this article
Cite this article
Kang, S., Blache, C.A., Bajana, S. et al. The effect of soluble E-selectin on tumor progression and metastasis. BMC Cancer 16, 331 (2016). https://doi.org/10.1186/s12885-016-2366-2
- Shear-resistant adhesion
- Hematogenous metastasis